US3862317A - Reducing dependence on tobacco - Google Patents

Reducing dependence on tobacco Download PDF

Info

Publication number
US3862317A
US3862317A US217960A US21796072A US3862317A US 3862317 A US3862317 A US 3862317A US 217960 A US217960 A US 217960A US 21796072 A US21796072 A US 21796072A US 3862317 A US3862317 A US 3862317A
Authority
US
United States
Prior art keywords
avena
plant
tobacco
reducing substance
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US217960A
Other languages
English (en)
Inventor
Anand Chaman Lal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of US3862317A publication Critical patent/US3862317A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane

Definitions

  • Tobacco is the fermented leaves of a plant of the genus Nicotiana, especially N. tabacum.
  • tobacco may be consumed by chewing or as snuff, but is more usually smoked.
  • tobacco consumption has undesirable long-termeffects.
  • Lung cancer in particular, has been shown to be associated in a statistically very significant way with heavy smoking, especially of cigarettes. Other undesirable long-tern effects have been noted.
  • Group 1 before (mean 19.5 i 2.0 s.e.) is not statistically separable from-Group 2 before (mean 16.5 i 1.7 s.e.)', 1.33, 0.30 P 0.20.
  • Group 2 before is not different from Group 2 after. (mean 16.9 :1.4 s.e.); z 0.180, 0.90 P 0.80.
  • the present invention therefore provides a method of reducing dependence on tobacco which comprises administering to a person dependent thereon an extract of part or all of an Avena plant, especially A. saliva, the cultivated oat.
  • an Avena plant especially A. saliva, the cultivated oat.
  • Other species of Avena e.g. A. fatua, A. steritis, and A. strigosa, can also be used.
  • an appropriate solvent e.g. water, ethyl alcohol, acetone, a chlorinated hydrocarbon such as chloroform, diethyl ether, or hexane.
  • solvents especially aqueous ethyl alcohol, can also be used.
  • the extraction is conveniently carried out at ambient temperature, e.g. l025C., though higher temperatures which do not adversely affect the extract, e.g. up to 50C., can also be used.
  • the period of extraction can be from a few hours to several, e.g. 2 to 3 days.
  • the plant should be crushed or comminuted before it is mixed with the solvent. From 1 to 10, preferably about 2 to 4, parts by volume of solvent are used per part by weight of the plant. After the extraction, the plant remains may be removed by filtration or other convenient means.
  • the extract so produced may be used as it is, or after dilution with the same or another such solvent miscible therewith, e.g. water.
  • a physiologically unacceptable solvent when used, it must be removed, e.g. by evaporation at low pressure. The residue of the extract which then remains may be used as such or after Name Aerosil.”
  • the material with the extract from the Avena plant absorbed or adsorbed thereon may be formulated into a capsule or tablet by conventional means, using conventional, pharmaceutically acceptable carrier materials.
  • EXAMPLE 1 A quantity of healthy, fresh, whole Avena saliva plant, collected just before harvest, is extracted with parts by volume of 90% ethyl alcohol water) to 1.5 parts by weight of crushed plant i.e. 5 litres of 90% ethyl alcohol to 1.5 kg. of plant. The mixture is kept at room temperature for 72 hours with frequent agitation and then filtered to yield a clear, ambercoloured liquid. For administration to cigarette smokers, 1 ml. of the extract is diluted to 5 ml. with water and administered four times a day. Flavouring and preservatives may be added, as desired.
  • EXAMPLE 2 The liquid extract obtained by the procedure of Example l is contacted with a quantity of a silica powder of particle size 3 to mp., sold under the Trade Name Aerosil, in the proportion of 1 ml. of extract to l g. of silica, whereby the substance or substances present in the extract and derived from the Avena saliva plant is absorbed by or adsorbed on the silica.
  • the solvent is allowed to evaporate to yield a free-flowing powder which is then mixed with the ingredients shown in the following formula:
  • silica containing substance(s) extracted from Avena plant 1,000 lactose 300 microcrystalline cellulose 250 magnesium stearate 50 1,600
  • This mixture is then compressed to form a tablet suitable for oral administration.
  • EXAMPLE 3 A silica powder, containing the substance or substances extracted from the Avena plant, is obtained by the procedure of Example 2 and blended with 10% by weight of lactose, 2% by weight of starch and 1% by weight of magnesium stearate. This mixture is compressed into slugs and the slugs are inserted into hard gelatin capsules of suitable size for oral administration.
  • EXAMPLE 4 The liquid extract obtained in Example 1 is used to fill dropper bottles of suitable size, e.g. 100 ml., which are then used to administer a measured dose of 1 ml. of the liquid, delivered by a dropper of 1 ml. capacity.
  • the measured dose may be delivered into a glass of water as diluent, or onto a suitable carrier, e.g. a sugar lump.
  • EXAMPLE 5 The liquid extract obtained by the procedure of Example l is evaporated in vacuo to yield 2% by weight of a gummy residue, which is triturated with diethyl ether and the latter solvent is removed by vacuum evaporation. The solid residue is then suspended in water together with sodium carboxymethyl cellulose (5% by weight, based on the water content) and flavouring, to give an aqueous suspension suitable for oral adminstration.
  • the extracts of Avena are normally administered orally in a dosage corresponding to the extract of about 1 to 1.5 grams of the whole green plant per day. This dosage is preferably divided, e.g. into quarters which are separately administered as in the trial described above. Any suitable dosage form, e.g. any one of the compositions described in the Examples above, may be used.
  • a method of reducing dependence on tobacco which comprises administering orally to a person dependent thereon a sufficient amount of a tobacco dependence reducing substance extracted from a whole mature green Avena plant selected from the group consisting of Avena sativa, Avena steritis, Avena strigosa and Avena fatua to reduce said dependence, the tobacco dependence reducing substance corresponding to that obtained by solvent extraction of said Avena plant with from about 1 to 10 parts by volume of solvent per part by weight of plant, the extraction being carried out at from ambient temperature to 50C. and said solvent being selected from the group consisting of water, ethyl alcohol, acetone, 21 chlorinated hydrocarbon, diethyl ether, hexane or mixtures thereofv 2.
  • the tobacco dependence reducing substance is extracted from the Avena plant with a solvent selected from the group consisting of water, ethyl alcohol or mixtures thereof.
  • the tobacco dependence reducing substance is obtained by extracting an Avena sativa plant with about aqueous ethyl alcohol at substantially ambient temperature.
  • Avena plant is Avena sativa, the cultivated oat plant.
  • a composition for oral administration to reduce dependence on tobacco which comprises a tobacco dependence reducing substance extracted from a whole the group consisting of water, ethyl alcohol, acetone, a chlorinated hydrocarbon, diethyl ether, hexane or mixtures thereof.
  • composition according to claim 8 in the form of a capsule or tablet.
  • composition according to claim 8 in the form of a syrup or elixir.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
US217960A 1971-01-16 1972-01-14 Reducing dependence on tobacco Expired - Lifetime US3862317A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB223171A GB1383903A (en) 1971-01-16 1971-01-16 Reducing dependence on tobacco

Publications (1)

Publication Number Publication Date
US3862317A true US3862317A (en) 1975-01-21

Family

ID=9735907

Family Applications (1)

Application Number Title Priority Date Filing Date
US217960A Expired - Lifetime US3862317A (en) 1971-01-16 1972-01-14 Reducing dependence on tobacco

Country Status (9)

Country Link
US (1) US3862317A (enrdf_load_stackoverflow)
AT (1) AT314091B (enrdf_load_stackoverflow)
AU (1) AU3796172A (enrdf_load_stackoverflow)
BE (1) BE778010A (enrdf_load_stackoverflow)
CH (1) CH559041A5 (enrdf_load_stackoverflow)
DE (1) DE2201797A1 (enrdf_load_stackoverflow)
ES (1) ES398876A1 (enrdf_load_stackoverflow)
FR (1) FR2157769B1 (enrdf_load_stackoverflow)
GB (1) GB1383903A (enrdf_load_stackoverflow)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055478A (en) * 1986-06-19 1991-10-08 Cooper Thomas M Method for stopping smoking
US6447815B1 (en) 2000-12-19 2002-09-10 Access Business Group International Llc Heated alcohol extraction of herbs
WO2009080004A3 (de) * 2007-12-22 2009-10-29 Ds-Pharma Gmbh Gersten- oder haferextrakt zur raucherentwöhnung

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2357756A (en) * 1942-01-03 1944-09-05 Musher Foundation Inc Process of preparing a vitamin b complex concentrate
US2600700A (en) * 1949-03-08 1952-06-17 Colburn J Smith Composition for alleviation of the tobacco habit

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2357756A (en) * 1942-01-03 1944-09-05 Musher Foundation Inc Process of preparing a vitamin b complex concentrate
US2600700A (en) * 1949-03-08 1952-06-17 Colburn J Smith Composition for alleviation of the tobacco habit

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055478A (en) * 1986-06-19 1991-10-08 Cooper Thomas M Method for stopping smoking
US6447815B1 (en) 2000-12-19 2002-09-10 Access Business Group International Llc Heated alcohol extraction of herbs
WO2009080004A3 (de) * 2007-12-22 2009-10-29 Ds-Pharma Gmbh Gersten- oder haferextrakt zur raucherentwöhnung

Also Published As

Publication number Publication date
AU3796172A (en) 1973-07-19
BE778010A (fr) 1972-07-13
FR2157769A1 (enrdf_load_stackoverflow) 1973-06-08
ES398876A1 (es) 1974-08-16
GB1383903A (en) 1974-02-12
CH559041A5 (enrdf_load_stackoverflow) 1975-02-28
FR2157769B1 (enrdf_load_stackoverflow) 1975-12-26
AT314091B (de) 1974-03-25
DE2201797A1 (de) 1972-07-27

Similar Documents

Publication Publication Date Title
WO2020239035A1 (zh) 一种香烟添加剂及其制备方法与应用
CN102697781B (zh) 胡芦巴碱作为制备防治糖尿病及其并发症药物的应用
CN109998151A (zh) 中链甘油三酯在改善和/或减少呼吸道刺激中的应用
US3862317A (en) Reducing dependence on tobacco
KR101117669B1 (ko) 인삼이 포함된 니코틴 제거효과가 있는 금연재 약학 조성물
JPS6355485B2 (enrdf_load_stackoverflow)
CN100488533C (zh) 一种用于治疗和改善支气管呼吸困难的草药组合物
KR102550993B1 (ko) 기관지 기능의 개선 또는 면역기능의 증강을 위한 건강기능식품
CN111569011A (zh) 一种中药组合物的新用途及其制备方法
WO2016019736A1 (zh) 用于治疗咳嗽及减轻气道炎症的五味子提取物、其制备方法及应用
US20030104005A1 (en) Physiologically active compositions based upon active ingredients of basidiomycotina and araliaceae
RU2066196C1 (ru) Средство "антиник" для облегчения отвыкания от табакокурения и лечения хронических бронхолегочных заболеваний курильщиков
EP1498131B1 (en) Medicinal preparation containing phenylethanoid glycosides extracted from Cistanche tubulosa
KR102094228B1 (ko) 운카리아 린초필라 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 조성물
KR20040047617A (ko) 니코틴제거 효과가 있는 조성물 및 그 제조 방법
KR102421081B1 (ko) 나이아신을 포함하는 금연 보조제 조성물
CN112043786B (zh) 一种具有戒烟功效的中药组合物及其制备方法和应用
CN109731068B (zh) 具有抗化学性肝损伤功能的组合物、制备方法及应用
AU2021101213A4 (en) Rabdosia Serra composition and its application
KR0179088B1 (ko) 홍경천 추출물을 함유하는 당뇨병 예방 및 치료제 조성물
CN117017889B (zh) 一种用于缓解口干症的组合物
CN103977076B (zh) 五味子总木脂素在制备用于治疗咳嗽的药物中的应用
AU2001230492A1 (en) Antimonocytic activity of extracts of piper betel leaves
WO2002045730A1 (en) Antimonocytic activity of extracts of piper betel leaves
WO2015172613A1 (zh) 五味子总多糖在制备用于治疗咳嗽的药物或保健品中的应用